I don't know that they've really delayed financial guidance as much as intending to do it when they announce quarterly and annual results. That's when the guidance should be expected, not at the JPM conference.
That said, today the expiration of the calls I held and while I did make some money, and add some shares, my decision to wait to the end was costly, as clearly the presentation yesterday didn't buoy the stock.
For all I know next week we could get a partnership, but it might be next month, or even next year, the company is playing their hand very close to the vest. Frankly it's no differently than they've done for years as little indication has ever been given to something coming to fruition since Mitch used "SOON" and it seemed to mean any time in the next few years.
I believe the drugs are going in the right direction and I just hope that if partnerships are made, they maintain sufficient ownership of the products to make them profitable in the future. It was pointed out that Kadcyla sales topped a billion, but unfortunately while it's a success for Roche, because we fully monetized it, we see nothing more. I know most investors don't like dilution, but I believe SGEN has been successful because they diluted when the time was right, while IMGN had the opportunity, but failed to do it, I'd rather have had the dilution, and still owned a position in Kadcyla sales.